Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

November 30, 2021

Dr. Julia Edwards Findings Promising Zone Designs

The aim of any clinical research is to detect the actual difference in treatment effect between two groups (power) and...

Read article

June 18, 2021

Use of Scoring Functions for Clinical Trial Optimization

Next week’s PSI Conference will feature Dr. Yannis Jemiai speaking on the use of Scoring Functions in the re-imagined...

Read article

June 15, 2021

The Promising Zone Ten Years Later

Ten years ago, a seminal paper published by Cytel Founder Cyrus Mehta, introduced the Promising Zone Design to...

Read article

June 9, 2021

Selecting a Clinical Trial Design: How Broadly Should You Explore?

When selecting clinical trial designs, how many design options should a sponsor explore? Would a sponsor feel more...

Read article

June 2, 2021

A Data-Infused Approach to De-Risking Clinical Trials

For many decades the Pareto Frontier has been employed by actors in the private sector to evaluate and understand the...

Read article